124 related articles for article (PubMed ID: 30942640)
1. Refractoriness to rituximab-based therapy and elevated serum B2-microglobulin predict for inferior survival in marginal zone lymphoma.
Sorigue M; Bishton M; Domingo-Domenech E; McMillan A; Prusila R; García O; Kuusisto M; Condom M; Tapia G; Ribera JM; Kuittinen O; Fox CP; Sancho JM
Leuk Lymphoma; 2019 Oct; 60(10):2524-2531. PubMed ID: 30942640
[TBL] [Abstract][Full Text] [Related]
2. Refractoriness to immunochemotherapy in follicular lymphoma: Predictive factors and outcome.
Sorigue M; Mercadal S; Alonso S; Fernández-Álvarez R; García O; Moreno M; Pomares H; Alcoceba M; González-García E; Motlló C; González-Barca E; Martin A; Sureda A; Caballero D; Ribera JM; Sancho JM
Hematol Oncol; 2017 Dec; 35(4):520-527. PubMed ID: 28156010
[TBL] [Abstract][Full Text] [Related]
3. Dual institution experience of nodal marginal zone lymphoma reveals excellent long-term outcomes in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJ; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Br J Haematol; 2016 Oct; 175(2):275-280. PubMed ID: 27443247
[TBL] [Abstract][Full Text] [Related]
4. Prognostic impact of β₂-microglobulin in patients with non-gastric mucosa-associated lymphoid tissue lymphoma.
Yoo C; Yoon DH; Yoon S; Kim S; Huh J; Park CJ; Lee SW; Suh C
Leuk Lymphoma; 2015 Mar; 56(3):688-93. PubMed ID: 24913511
[TBL] [Abstract][Full Text] [Related]
5. Splenic marginal zone lymphoma: excellent outcomes in 64 patients treated in the rituximab era.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Cooper BW; De Lima MJG; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Hematology; 2017 Aug; 22(7):405-411. PubMed ID: 28105889
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Yoon DH; Yang DH; Lee WS; Kim HJ; Yhim HY; Jeong SH; Won JH; Lee S; Kong JH; Lim SN; Ji JH; Kwon KA; Lee GW; Lee JH; Lee HS; Shin HJ; Suh C
Cancer Commun (Lond); 2019 Oct; 39(1):58. PubMed ID: 31619290
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
[TBL] [Abstract][Full Text] [Related]
8. Serum beta-2 microglobulin as a prognostic biomarker in patients with mantle cell lymphoma.
Yoo C; Yoon DH; Kim S; Huh J; Park CS; Park CJ; Lee SW; Suh C
Hematol Oncol; 2016 Mar; 34(1):22-7. PubMed ID: 25689467
[TBL] [Abstract][Full Text] [Related]
9. Rare lymphomas in routine practice - Treatment and outcome in marginal zone lymphoma in the prospective German Tumour Registry Lymphatic Neoplasms.
Knauf W; Abenhardt W; Koenigsmann M; Maintz C; Sandner R; Zahn MO; Schnell R; Tech S; Kaiser-Osterhues A; Houet L; Marschner N;
Hematol Oncol; 2021 Aug; 39(3):313-325. PubMed ID: 33942348
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of oxaliplatin and prednisone for patients with relapsed or refractory marginal zone lymphoma: Consortium for Improving Survival of Lymphoma trial.
Oh SY; Kim WS; Kim JS; Chae YS; Lee GW; Eom HS; Ryoo HM; Lee S; Kim SJ; Yoon DH; Won JH; Hong J; Park J; Lee SM; Hong JY; Park E; Kim HJ; Yang DH; Kim HJ; Suh C
Leuk Lymphoma; 2016; 57(6):1406-12. PubMed ID: 26413982
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in follicular lymphoma: the importance of beta-2 microglobulin.
Cánovas A; Alonso JJ; Barreiro G; Aguirre C
Tumori; 2010; 96(1):117-21. PubMed ID: 20437868
[TBL] [Abstract][Full Text] [Related]
12. Risk adapted approach: How to treat splenic marginal zone lymphoma in resource-poor settings? - The real-life experience of a Brazilian cancer treatment center.
de Pádua Covas Lage LA; Dos Santos FFC; Levy D; Moreira FR; Couto SCF; Culler HF; de Oliveira Costa R; Rocha V; Pereira J
BMC Cancer; 2020 Aug; 20(1):717. PubMed ID: 32746790
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.
Iannitto E; Bellei M; Amorim S; Ferreri AJM; Marcheselli L; Cesaretti M; Haioun C; Mancuso S; Bouabdallah K; Gressin R; Tripodo C; Traverse-Glehen A; Baseggio L; Zupo S; Stelitano C; Castagnari B; Patti C; Alvarez I; Liberati AM; Merli M; Gini G; Cabras MG; Dupuis J; Tessoulin B; Perrot A; Re F; Palombi F; Gulino A; Zucca E; Federico M; Thieblemont C
Br J Haematol; 2018 Dec; 183(5):755-765. PubMed ID: 30407629
[TBL] [Abstract][Full Text] [Related]
14. Stage IV marginal zone B-cell lymphoma--prognostic factors and the role of rituximab: Consortium for Improving Survival of Lymphoma (CISL) study.
Oh SY; Kim WS; Kim JS; Kim SJ; Lee S; Lee DH; Won JH; Hwang IG; Kim MK; Lee SI; Chae YS; Yang DH; Kang HJ; Choi CW; Park J; Kim HJ; Kwon JH; Lee HS; Lee GW; Eom HS; Kwak JY; Suh C; Kim HJ
Cancer Sci; 2010 Nov; 101(11):2443-7. PubMed ID: 20831770
[TBL] [Abstract][Full Text] [Related]
15. A prognostic index for extranodal marginal-zone lymphoma based on the mucosa-associated lymphoid tissue International Prognostic Index and serum β2-microglobulin levels.
Kim HD; Cho H; Jeong H; Bang K; Kim S; Lee K; Kang EH; Park JS; Park CS; Huh J; Ryu JS; Lee SW; Yoon DH; Oh SY; Suh C
Br J Haematol; 2021 Apr; 193(2):307-315. PubMed ID: 33216979
[TBL] [Abstract][Full Text] [Related]
16. Presence of a high-grade component in gastric mucosa-associated lymphoid tissue (MALT) lymphoma is not associated with an adverse prognosis.
Ang MK; Hee SW; Quek R; Yap SP; Loong S; Tan L; Tao M; Lim ST
Ann Hematol; 2009 May; 88(5):417-24. PubMed ID: 18777110
[TBL] [Abstract][Full Text] [Related]
17. Beta-2-microglobulin levels in patients with extranodal B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT)-type: a retrospective analysis.
Penz MZ; Fiebiger WC; Valencak JB; Osterreicher C; Ba-Ssalamah A; Formanek M; Brodowic T; Chott A; Raderer M
Anticancer Res; 2001; 21(4B):3049-52. PubMed ID: 11712809
[TBL] [Abstract][Full Text] [Related]
18. Lenalidomide plus rituximab (R
Becnel MR; Nastoupil LJ; Samaniego F; Davis RE; You MJ; Green M; Hagemeister FB; Fanale MA; Fayad LE; Westin JR; Wang M; Oki Y; Forbes SG; Feng L; Neelapu SS; Fowler NH
Br J Haematol; 2019 Jun; 185(5):874-882. PubMed ID: 30919940
[TBL] [Abstract][Full Text] [Related]
19. CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.
Hsu A; Kurt H; Zayac AS; Olszewski AJ
Leuk Lymphoma; 2022 Jan; 63(1):31-42. PubMed ID: 34467833
[TBL] [Abstract][Full Text] [Related]
20. High-dose therapy and autologous stem cell transplantation in marginal zone lymphomas: a retrospective study by the EBMT Lymphoma Working Party and FIL-GITMO.
Avivi I; Arcaini L; Ferretti VV; Boumendil A; Finel H; Milone G; Zaja F; Liliana D; Musso M; Didier B; Bachy E; Wattad M; Nicolas-Virelizier E; Gramatzki M; Bourhis JH; Caillot D; Haenel A; Held G; Thieblemont C; Jindra P; Pohlreich D; Guilhot F; Kroschinsky F; Wahlin B; Scheid C; Ifrah N; Berthou C; Dreger P; Montoto S; Conconi A
Br J Haematol; 2018 Sep; 182(6):807-815. PubMed ID: 29984825
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
